D H Johnson - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

D H Johnson

Showing results (361-370 of 376) with videos related to

Pageof 38

Sort By:

Lung Cancer (Amsterdam, Netherlands)|September 18, 2002

The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancerS M Keller, M G Vangel, S Adak, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1992

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study GroupB J Roth, D H Johnson, L H Einhorn, et al.

The Oncologist|October 21, 2000

Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue CoalitionG A Curt, W Breitbart, D Cella, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999

Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancerR F DeVore, D H Johnson, J Crawford, et al.

Clinical Nuclear Medicine|June 1, 1992

Staging lung carcinoma with a Tc-99m labeled monoclonal antibodyJ P Vansant, D H Johnson, D M O'Donnell, et al.

International Journal of Radiation Oncology, Biology, Physics|October 23, 1997

Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology GroupR Komaki, C B Scott, W T Sause, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2001

Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant TherapyJ H Schiller, S Adak, R H Feins, et al.

Journal of the National Cancer Institute|December 10, 1997

Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working CadreM A Tucker, N Murray, E G Shaw, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004

Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trialK L Tedesco, A D Thor, D H Johnson, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2004

Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancerJ V Heymach, D H Johnson, F R Khuri, et al.

Pageof 38

Search research articles

Showing results (361-370 of 376) with videos related to

Sort By:

Pageof 38

Lung Cancer (Amsterdam, Netherlands)|September 18, 2002

The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancerS M Keller, M G Vangel, S Adak, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1992

The Oncologist|October 21, 2000

Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue CoalitionG A Curt, W Breitbart, D Cella, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999

Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancerR F DeVore, D H Johnson, J Crawford, et al.

Clinical Nuclear Medicine|June 1, 1992

Staging lung carcinoma with a Tc-99m labeled monoclonal antibodyJ P Vansant, D H Johnson, D M O'Donnell, et al.

International Journal of Radiation Oncology, Biology, Physics|October 23, 1997

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2001

Journal of the National Cancer Institute|December 10, 1997

Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working CadreM A Tucker, N Murray, E G Shaw, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004

Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2004

Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancerJ V Heymach, D H Johnson, F R Khuri, et al.

Pageof 38